MBF-118

About Medibiofarma

Medibiofarma is a private, clinical-stage biotech based in Madrid, Spain, advancing a pipeline of novel small molecules. Its lead asset, MBF-118, has completed a Phase 2a trial for fibrotic Crohn's disease, positioning the company as a development-stage entity. The firm employs a capital-efficient, virtual discovery model, concentrating internal expertise on drug design, chemistry, and IP while outsourcing later-stage preclinical work. Its strategy is to de-risk assets through clinical proof-of-concept before seeking licensing partnerships.

Therapeutic Areas